Lv1
50 积分 2023-07-03 加入
Updated Phase 1 Results of a First-in-Human Open-Label Study of Lcar-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (Bcma)
5个月前
已完结
“There is always a better way”: Managing uncertainty in decision making about new cancer drugs in Canada
5个月前
已完结
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial
6个月前
已完结
Investigational antibody-drug conjugates in clinical trials for the treatment of breast cancer
6个月前
已完结
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
6个月前
已完结
Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)
6个月前
已完结
Magnitude of clinical benefit of trials supporting US Food and Drug Administration (FDA) approval of breakthrough and non-breakthrough drugs
6个月前
已完结
The FDA Breakthrough-Drug Designation — Four Years of Experience
6个月前
已完结
Quality and safety in medical 3D printing
6个月前
已完结
Quality and safety in medical 3D printing
6个月前
已关闭
皖公网安备34019202002308
